Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 25/2/2021
SIETES contiene 93212 citas

 1 a 20 de 51 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Wang DD, Li Y, Chiuve SE, Stampfer MJ, Manson JE, Rimm EB, Willett WC, Hu FB. Association of specific dietary fats with total and cause-specific mortality . JAMA Intern Med 2016;176:1134-45. [Ref.ID 100473]
2. Cita con resumen
Allen K, Pearson-Stuttard J, Hooton W, Diggle P, Capewell S, O’Flaherty M. Potential of trans fats policies to reduce socioeconomic inequalities in mortality from coronary heart disease in England: cost effectiveness modelling study. BMJ 2015;351:h4583. [Ref.ID 99541]
3. Cita con resumen
Kromhout D. Where the latest US dietary guidelines are heading. BMJ 2015;351:h4034. [Ref.ID 99394]
4. Cita con resumen
Anónimo. Icosapent ethyl (Vascepa) for severe hypertriglyceridemia. Med Lett Drugs Ther 2013;55:33-4. [Ref.ID 95656]
5. Cita con resumen
The Risk and Prevention Study Collaborative Group. N-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013;368:1800-8. [Ref.ID 95534]
6.Tiene citas relacionadas Cita con resumen
Ramsden CE, Zamora D, Leelarthaepin B, Majchrzak-Hong SF, Faurot KR, Suchindran CM, Ringel A, Davis JM, Hibbeln JR. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ 2013;346:12. [Ref.ID 94928]
7.Tiene citas relacionadas Cita con resumen
Calder PC. American Heart Association advice on omega 6 PUFAs cast into doubt. BMJ 2013;346:8. [Ref.ID 94926]
8. Cita con resumen
Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308:1024-33. [Ref.ID 93760]
9.Tiene citas relacionadas Cita con resumen
The ORIGIN Trial Investigators. n–3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-18. [Ref.ID 92638]
10. Cita con resumen
Palmer DJ, Sullivan T, Gold MS, Prescott SL, Heddle R, Gibson RA, Makrides M. Effect of n-3 long chain polyunsaturated fatty acid supplementation in pregnancy on infants' allergies in first year of life: randomised controlled trial. BMJ 2012;344:14. [Ref.ID 92405]
11. Cita con resumen
De Caterina R. N-3 fatty acids and cardiovascular disease. N Engl J Med 2011;364:2439-50. [Ref.ID 90939]
12. Cita con resumen
Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation. A ranzomized controlled trial. JAMA 2010;304:2363-72. [Ref.ID 89744]
13. Cita con resumen
Kromhout D, Giltay EJ, Geleijnse JM, for the Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363:2015-26. [Ref.ID 89676]
15.Tiene citas relacionadas
Tavazzi L, Tognoni G, on behalf of the GISSI-HF Steering Committee. N-3 polyunsaturated fatty acids and statins in heart failure. Authors' reply. BMJ 2009;373:380-1. [Ref.ID 85141]
16.Tiene citas relacionadas
Solfrizzi V, Capurso C, Vendemiale G, Capurso A, Panza F. N-3 polyunsaturated fatty acids and statins in heart failure. BMJ 2009;373:380. [Ref.ID 85140]
17.Tiene citas relacionadas
Florkowski C, Molyneux S, George P, Lever M, Richards M. N-3 polyunsaturated fatty acids and statins in heart failure. BMJ 2009;373:379-80. [Ref.ID 85139]
18.Tiene citas relacionadas
Parashar A. N-3 polyunsaturated fatty acids and statins in heart failure. BMJ 2009;373:379. [Ref.ID 85138]
19.Tiene citas relacionadas
Rupp H, Rupp TP, Alter P, Maisch B. N-3 polyunsaturated fatty acids and statins in heart failure. BMJ 2009;373:378-9. [Ref.ID 85137]
20.Tiene citas relacionadas
Gibson LM. N-3 polyunsaturated fatty acids and statins in heart failure. BMJ 2009;373:378. [Ref.ID 85136]
Seleccionar todas
 1 a 20 de 51 siguiente >>